Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of mgf peptide in China. Welcome to wholesale bulk high quality mgf peptide for sale here from our factory. Good service and reasonable price are available.
MGF Peptide (Mechanical Growth Factor) is a selective splicing variant of the insulin-like growth factor-1 (IGF-1) gene. As a self-secretive/paracrine signaling molecule produced immediately by the body in response to mechanical stimulation or tissue damage, its core function is to initiate local repair and regeneration programs. It activates specific signaling pathways (such as PI3K/Akt), strongly inhibits cell apoptosis, and recruits satellite cells and stem cells to the damaged site, promoting their proliferation and differentiation into functional cells. Compared to the systemic action of IGF-1, MGF has a shorter and more precise effect. Its unique C-terminal extension sequence is the key to its unique biological activity. Currently, its main value is concentrated in the field of regenerative medicine, aiming to explore its potential for repairing myocardial, neural, and skeletal muscle injuries. However, due to its extremely short half-life and poor stability, its clinical application still faces significant challenges. Advanced delivery systems are needed to achieve therapeutic efficacy.
|
|
|
MGF Powder COA
MGF (Mechano Growth Factor, mechanical growth factor) peptides are splicing variants of insulin-like growth factor-1 (IGF-1). Their production process involves genetic engineering, chemical synthesis and modification techniques, aiming to optimize their biological activity, stability and half-life. The following elaborates the manufacturing information of MGF peptides from four dimensions: molecular design, synthesis process, modification technology and quality control.
Molecular Design and Genetic Engineering Foundation
The production of MGF peptides begins with its unique molecular structure design. As a splicing variant of IGF-1, MGF contains a specific peptide segment of 24-25 amino acids at the C-terminal (such as the C-terminal sequence of human MGF is "QRRRKGSTFEEHK"), which is generated through selective splicing and confers its signal transduction ability independent of the IGF-1 receptor.
Gene cloning and expression:
Through PCR amplification, specific exons of the human IGF-1 gene (such as exon 4 and exon 6) were obtained and the MGF coding sequence was constructed.
The target gene was inserted into the expression vector (such as the pET series), and transformed into the Escherichia coli or yeast system for induced expression. For example, a certain study used the Pichia pastoris expression system and achieved efficient secretion expression of MGF through methanol induction, with a yield of 50mg/L.
Protein purification:
The target protein was separated using affinity chromatography (such as the His-tag-Ni column) or ion exchange chromatography, combined with ultrafiltration concentration and freeze-drying techniques to obtain high-purity powder. A commercial product had a purity of 98.77%, a molecular weight of 2868.19 Da, and met the research-grade standard.
|
|
|
Chemical synthesis: The mainstream application of solid-phase peptide synthesis (SPPS)
For short-chain MGF peptides (such as the C-terminal 24 peptide), chemical synthesis due to its high flexibility and accuracy has become the preferred method.
Solid-phase peptide synthesis process
Resin loading: Fix the first amino acid (such as Fmoc-Tyr-Wang resin) onto the resin carrier.
Sequential coupling: Add protecting amino acids (Fmoc/Boc strategy) one by one using condensing agents like DCC/HOBt or HATU, gradually extending the peptide chain.
Cutting and deprotection: Use TFA (trifluoroacetic acid) to cut the peptide chain and remove the side chain protecting groups simultaneously to obtain crude peptide.
Synthesis optimization
Amino acid substitution: To enhance stability, some manufacturing processes replace L-type arginine with D-type arginine (such as "D-Arg-D-Arg" structure), reducing the sensitivity to enzymatic degradation.
Fragment condensation: For long-chain peptides, adopt the strategy of segmental synthesis followed by liquid-phase condensation to improve synthesis efficiency. For example, a certain study divided MGF into N-terminal (1-12) and C-terminal (13-24) segments, and synthesized them separately before connecting them through a thioether bond.
Modification techniques: PEGylation and long-acting modification
The half-life of the natural MGF peptide is extremely short (only 5-7 minutes), limiting its clinical application. By PEG modification, the duration of action can be significantly extended.
PEG process:
Selection of activated PEG: Select linear or branched PEG-NHS esters with a molecular weight of 2000-5000 Da and react with the N-terminal amino group or lysine side chain of MGF peptide.
Site-specific modification: Introduce cysteine (Cys) into the MGF sequence through genetic engineering and use malonylhydrazide-PEG for specific coupling to reduce heterogeneity.
Long-lasting effect:
The half-life of PEG-MGF can be extended to 48-72 hours, significantly improving bioavailability. Animal experiments show that after a single injection of PEG-MGF, the activation rate of muscle satellite cells is three times higher than that of unmodified MGF, and the duration of action is five times longer.
Quality control: Strict control from raw materials to finished products
The manufacturing of MGF peptide must follow GMP standards to ensure product safety and consistency.
Raw material inspection
The amino acid raw materials must comply with USP/EP standards, with a purity of ≥ 99.5% and a heavy metal content of ≤ 10 ppm.
Resins and condensing agents need to provide COA (analysis certificate) to verify that the residual solvents (such as DMF) comply with ICH guidelines.
Process monitoring
The coupling efficiency at each step of the synthesis process needs to be detected by ninhydrin to ensure ≥ 99.0%.
After the crude peptide is purified by HPLC, the purity of the main peak needs to be ≥ 95% and the single impurity ≤ 0.5%.
Product release
The molecular weight needs to be confirmed by MS (mass spectrometry), the purity needs to be determined by HPLC, and the secondary structure needs to be verified by circular dichroism (CD).
Microbial limit testing (such as endotoxin < 0.1 EU/mg) and sterility test are mandatory items.
From local repair factors to systemic messengers
MGF (Mechano Growth Factor, mechanical growth factor) peptides are splicing variants of insulin-like growth factor-1 (IGF-1). Their molecular structure and functional characteristics enable them to play dual roles in local tissue repair and systemic signal transduction. From the activation of muscle stem cells to cross-organ collaborative repair, the biological effects of MGF have transcended the traditional cognitive framework and have become a research hotspot in the field of regenerative medicine.
Molecular Basis: Splicing Variants and Structural Specificity
MGF is generated through selective splicing from the IGF-1 gene. Compared to the mature IGF-1 (70 amino acids), it has an extended C-terminal region containing an 40-amino-acid E domain, resulting in a 110-amino-acid basic polypeptide. This structural difference confers unique functions to MGF:
Receptor binding specificity: MGF initiates signal transduction by binding to the IGF-1 receptor, but its E domain can independently activate muscle satellite cells without relying on the complete IGF-1 receptor pathway.
Enzymatic stability: The proline-arginine-rich region in the E domain can resist proteolysis, prolonging the half-life of MGF in local tissues to 2-4 hours (unmodified IGF-1 only 5-10 minutes).
Gelation tendency: The hydrophobic core of the E domain promotes MGF to form dimers or tetramers, enhancing its affinity for the cell membrane and improving local bioavailability.
Local repair: The "first responders" to muscle injury
After muscle injury, MGF dominates the early repair process through the following mechanisms:
Satellite cell activation
Within 30 minutes after injury, the local expression level of MGF increases by 10-15 times, activating quiescent satellite cells through the MAPK/ERK pathway and promoting their entry into the proliferation cycle.
Animal experiments show that the activation rate of satellite cells in MGF-deficient mice is reduced by 60%, and muscle regeneration is delayed by 3-5 days.
Protein synthesis regulation
MGF upregulates the activity of ribosomal protein S6 kinase (S6K1) through the mTOR pathway, increasing the rate of muscle protein synthesis by 40-60%.
When combined with IGF-1, MGF preferentially promotes the synthesis of myosin heavy chain (MHC), accelerating the transformation of muscle fiber types.
Anti-inflammatory and antioxidant
MGF can inhibit the assembly of NLRP3 inflammasome, reduce the release of IL-1β and TNF-α, and reduce the inflammatory response at the injury site.
By activating the Nrf2 pathway, it enhances the activity of superoxide dismutase (SOD), eliminating excessive reactive oxygen species (ROS).
System messengers: The collaborative network for cross-organ repair
Recent studies have revealed that MGF can achieve distant tissue repair through the circulation or exosomes:
Cardiac protection
In the myocardial infarction model, local injection of MGF can reduce the infarct area by 25%, and it can also be transported through the blood to the liver, activating the secretion of IGF-1 in liver cells, forming a "cardiac-liver" repair axis.
MGF can improve the calcium ion processing ability of myocardial cells and reduce the risk of arrhythmia.
Neural regeneration
The brain ischemia model shows that MGF can penetrate the blood-brain barrier, promoting the proliferation of neural stem cells in the hippocampus, and increasing the survival rate of neurons by 35%.
The mechanism involves inhibiting the activity of GSK-3β, stabilizing the β-catenin protein, and activating the Wnt/β-catenin signaling pathway.
Skin and cartilage repair
In the chronic wound model, MGF accelerates epidermal regeneration by upregulating the synthesis of collagen XVIII and hyaluronic acid, reducing scar thickness by 40%.
In the osteoarthritis model, MGF can inhibit the expression of MMP-13, reduce the degradation of cartilage matrix, and promote the proliferation of chondrocytes.
Clinical Translation: Challenges from Laboratory to Application
Although MGF shows great potential, its clinical application still faces multiple obstacles:
Optimization of administration methods
The half-life of natural MGF is short (5-7 minutes), so long-acting preparations (such as PEG-MGF) or nanocarrier systems need to be developed.
Local injection may cause muscle fibrosis, so targeted delivery technologies (such as antibody-drug conjugates) need to be explored.
Dosage and safety
High doses of MGF may cause insulin resistance, so a dose-effect relationship model needs to be established.
Long-term use may induce antibody production, so humanization modification to reduce immunogenicity is necessary.
Indications selection
Current evidence supports the use of MGF for muscle atrophy and as an adjunctive treatment for myocardial infarction, but more III-phase clinical trials are needed for verification.
In the field of anti-aging, the potential risks of MGF (such as promoting tumor growth) need to be strictly evaluated.
Future directions: Precise regulation from a systems biology perspective
With the development of single-cell sequencing and spatial transcriptomics technologies, the regulatory network of MGF is gradually being deciphered:
Temporal dynamics
The expression of MGF after injury shows a bimodal pattern (local peak in the early stage and systemic release in the later stage), and a temporal dosing strategy needs to be developed.
Cell type specificity
The activation efficiency of MGF on satellite cell subpopulations (such as Pax7+/Myf5+ cells) varies significantly, and key regulatory factors need to be identified through CRISPR screening.
Metabolic reprogramming
MGF can induce muscle cells to shift from glycolysis to oxidative phosphorylation, improving energy utilization efficiency. This mechanism may provide a new target for the treatment of metabolic diseases.
Hot Tags: mgf peptide, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, Cosmetic, DERMORPHIN, dermorphin in humans, dermorphin peptide, Melanotan ii powder